Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment
The rare neurodegenerative disorder has no cure and no approved treatments
Read More
The rare neurodegenerative disorder has no cure and no approved treatments
Read MoreMar 9, 2026 | News, Regulatory
The approval was based on phase 3 data showing survival rates of 83.3% after three years
Read MoreMar 6, 2026 | News, Healthcare
The US state investment will go to 33 community-based organisations
Read MoreMar 4, 2026 | News, Regulatory
The autoimmune disease affects approximately three to five million people globally
Read MoreMar 3, 2026 | News, Healthcare
Construction is expected to be completed in phases from the end of 2027 into 2028
Read MoreMar 2, 2026 | News, Healthcare
The draft guidance specifically discusses genome editing and RNA-based therapies
Read MoreFeb 27, 2026 | News, Healthcare
The study finds that healthcare settings are a leading source of stigma for people living with rare conditions
Read MoreFeb 26, 2026 | News, Healthcare
The companies aim to develop next-generation oral medicines for obesity and diabetes
Read MorePH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Read MoreFeb 24, 2026 | News, Healthcare
The reduction in price to $675 will take effect at the beginning of next year
Read MoreFeb 24, 2026 | News, Regulatory
This is the first approved treatment option in the UK for patients with non-segmental vitiligo
Read MoreThe conference will take place from 6 to 7 October 2026 in Copenhagen, Denmark
Read More
